Shares of Enliven Therapeutics, Inc. (ELVN) have gained 0.8% over the past four weeks to close the last trading session at $19.92, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of$41.13 indicates a potential upside of 106.5%.The average comprises eight short-term price targets ranging from a low of $33.00 to a high of$52.00, with a standard deviation of $6.66. While the lowest ...